New chemo formula aims for fewer side effects in cancer fight
NCT ID NCT02909036
Summary
This study is testing a new, more stable version of a standard chemotherapy drug called melphalan. The goal is to see if this new formulation can be dosed more precisely and might cause fewer side effects like kidney or heart damage. It is for adults with multiple myeloma or AL amyloidosis who are getting a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.